Industrifonden
Industrifonden is a Swedish evergreen venture capital fund, founded in 1979 and headquartered in Stockholm. With ~$600M in assets, it backs early-stage companies from seed to Series A across Deep Tech, Life Science, and Transformative Tech — primarily in Sweden and the broader Nordics. [1]
Funder analysis
Web-researched analysis· 25 Jul 2026· v7What they fund
Pre-seed to Series A companies in Sweden and the Nordics, with a first ticket size of 10–50 million SEK. [1], Deep Tech ventures in advanced materials, energy, and computing, such as KISAB and ZeroPoint Technology. [1], Life Science companies addressing unmet medical needs, including clinical-stage biotech like AnaCardio and Asgard Therapeutics. [1], Transformative B2B software and industrial tech, like TrusTrace and Telness Tech, focusing on scalability and societal impact. [1]
Investment thesis
Industrifonden is Sweden’s national venture capital fund, investing in early-stage companies from seed to Series A across the Nordic region. The fund strategically backs transformative innovations within Life Science, Deep Tech, and Transformative Tech, encompassing critical areas such as biotech, medtech, healthtech, AI, advanced materials, and industrial digitalization. [1]
- Societal Impact & Innovation — The core thesis is to back transformative ventures with the power to change the way people live for the better, specifically seeking unique, scalable innovations that have a meaningful impact on our society. [1]
- Deep Tech & Advanced Materials — Focuses on advanced technology addressing important societal issues, with special interest in advanced materials, industry 4.0, energy, advanced computing, AI, and synthetic biology. [1]
- Life Science Commercialization — Invests in the commercialization of products and services grounded in solid science, addressing unmet medical needs, with expertise in biotech, medtech, and healthtech. [1]
- Transformative B2B Tech — Invests in transformative tech and business models to create the industry of tomorrow, mostly staying within the B2B space but investing in a broad range of industry verticals. [1]
Value add
Industrifonden provides credibility and network access, as highlighted by TrusTrace's CEO, who noted their pivotal role as an early investor. [1] They also offer experience in scaling companies globally, as mentioned by Telness Group's founder. [1] Fit verdict: Ideal for Nordic founders seeking long-term capital and strategic guidance in deep tech or life science. Founder diligence script: 1. What is your expected timeline for a follow-on investment? 2. How do you typically engage with the board? 3. Can you share examples of portfolio companies you've helped scale globally? 4. What is your typical ownership target in early-stage deals? 5. How do you support regulatory navigation in life science?
Portfolio focus
Biotech and Medtech: AnaCardio (heart failure treatment), Asgard Therapeutics (cancer immunotherapy), Bonesupport (orthopedic implants), and Pixelgen (protein interactomics). [1][2], Industrial Tech & Advanced Materials: Cascade Drives (hydraulics electrification), KISAB (silicon carbide substrates), and ZeroPoint Technology (server efficiency). [1], B2B Software & Telecom: TrusTrace (supply chain traceability), Telness Tech (cloud-based telecom), and EnginZyme (cell-free biomanufacturing). [1]
Notable investments & exits
Bonesupport: A Swedish biotech company that went public, with Industrifonden as a key investor. [2]
Strategic implications
Industrifonden's evergreen structure and focus on deep tech/life science provide a stable, long-term capital source for Nordic founders, reducing the pressure for quick exits. Their strong track record in scaling companies globally (e.g., Telness, TrusTrace) makes them a valuable partner for founders aiming for international expansion. The fund's societal impact mandate may attract LPs and partners focused on ESG, but could also limit investment in non-impactful, high-growth sectors.
Where they could go further
Expand investment in consumer/lifestyle and defense sectors, which are currently underrepresented in their portfolio. Develop a more structured co-investment program with international VCs to enhance global network access for Nordic founders. Increase focus on Series B and growth-stage investments to support portfolio companies beyond the early stages. Enhance transparency around board involvement and decision-making processes to build stronger founder trust.